ModifiedmhnPolicy CP.PMN.136

Mecamylamine (Vecamyl) for hypertension

Policy governing medical necessity and prior authorization criteria for mecamylamine (Vecamyl) for treatment of moderately severe to severe essential hypertension and certain malignant hypertension, affecting providers submitting requests for members under the payer's lines of business.

Policy Summary

Payermhn

PolicyMecamylamine (Vecamyl) for hypertension

Policy CodePolicy CP.PMN.136

Change TypeStep therapy bypass added (IL)Commercial approval durations revised

Effective DateJun 1, 2017

Next Review Date

Key ActionSubmit prior authorization with documentation showing diagnosis, age ≥18, and failure of three formulary antihypertensive classes (unless IL HIM bypass applies).

SourceLink

POLICY UPDATE CHANGES

Step therapy bypass for Illinois HIM requests per IL HB 5395 was added.

Approval durations for Commercial line of business were updated to 6 months (initial) and 12 months (continued).

≥3step therapy required failed classes

6 monthsinitial approval (Commercial)

12 monthscontinued approval

2.5 mg BIDinitial dosing

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

IL step therapy bypass

Coverage Criteria

Initial Therapy - Hypertension

Covered when ALL of the following are met:

Hypertension initial therapy: 1) Diagnosis of hypertension;N/A

Hypertension initial therapy: 2) Age ≥ 18 years;≥ 18 years

Hypertension initial therapy: 3) Failure of a combination of 3 formulary antihypertensive agents, each from different classes, at up to maximally indicated doses unless clinically significant adverse effects occur or all are contraindicated; (For Illinois HIM requests, the step therapy requirements do not apply as of 1/1/2026 per IL HB 5395).3 drug classes

Approval duration: 6 months

Continued Therapy - Hypertension

Covered when ALL of the following are met:

Hypertension continued therapy: 1) Member currently receiving medication via Centene benefit or previously met initial approval criteria, or member is under applicable continuity-of-care regulations;N/A

Hypertension continued therapy: 2) Member is responding positively to therapy.N/A

Approval duration: 12 months

Other Indications / Off-label routing

Covered when ONE of the following applies:

Label change routing: 1) The drug has undergone a label change within the last 6 months not yet reflected in this policy (e.g., new indication, age expansion, new dosing); follow the applicable formulary/no-coverage/non-formulary policies for the relevant line of business as listed in the policy (see CP.CPA.190, HIM.PA.33, CP.PMN.255, HIM.PA.103, CP.PMN.16).6 months

Refer to the listed line-of-business policies for routing

Off-label routing: 2) If the requested use (diagnosis, age, dosing) is not listed under section III and criterion 1 does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 (Commercial), HIM.PA.154 (Health Insurance Marketplace), or CP.PMN.53 (Medicaid).N/A

See referenced off-label policies

Use of mecamylamine (Vecamyl) for non‑FDA approved indications that are not specifically addressed in this policy is not authorized for coverage unless sufficient documentation of efficacy and safety is provided in accordance with the applicable off‑label use policy or evidence of coverage documents. Refer to the off‑label policies referenced by line of business (for example, CP.CPA.09 for Commercial, HIM.PA.154 for HIM, and CP.PMN.53 for Medicaid) when submitting requests for indications outside the FDA‑approved labeling.

Contraindications for mecamylamine include concomitant use with certain antibiotics or sulfonamides, coronary insufficiency, glaucoma, mild or moderate hypertension, organic pyloric stenosis, recent myocardial infarction, renal insufficiency, uremia, and hypersensitivity to mecamylamine. No boxed warnings are reported in this policy. Ensure these safety considerations are reviewed and documented when evaluating clinical appropriateness.

When state Medicaid coverage provisions conflict with this clinical policy, state Medicaid coverage provisions take precedence. Providers should consult the applicable state Medicaid manual for any jurisdiction‑specific coverage rules before relying solely on this policy for Medicaid members.

Requests for uses of mecamylamine that are not FDA‑approved and are not addressed in this policy may be denied unless adequate supporting documentation is submitted per the applicable off‑label use policy (see referenced policies by line of business). Providers should include clinical rationale, supporting literature, and relevant patient data to allow review under off‑label consideration pathways.

Coding and Age

Neutral coding referenceNDC

NDC not listed

No NDC provided in this policy

Referenced internal guideline IDsmixed

HIM.PA.154	Reference identifier for HIM off-label use (updated reference)
HIM.PHAR.21	Replaced reference identifier for HIM off-label use

Age

Minimum age≥ 18 years

ApplicabilityApplies to initial hypertension therapy criteria requiring diagnosis of hypertension

Source contextListed in hypertension initial therapy criteria (see approval duration: 6 months)

Provider Actions / Prior Authorization

Prior Authorization

Prior Authorization Required

Prior authorization is required for Mecamylamine (Vecamyl) for hypertension. PA decisions hinge on documented diagnosis of hypertension, member age, and completion of required step-therapy (or documented exceptions).

Prior authorization required before coverage is approved.
Key PA gates: diagnosis of hypertension, age ≥ 18, and step therapy failures (see step therapy callout).
Commercial LOB: see updated approval durations below.

Documentation Required

Required Clinical Documentation

Providers must submit clinical documentation to support that the member meets all approval criteria. Acceptable documentation includes office chart notes, labs, medication history, and any records showing prior trials, adverse effects, or contraindications.

Documented diagnosis of hypertension and age verification.

Background

Mecamylamine (Vecamyl) is an oral anti‑hypertensive agent classified as a ganglion blocker and is indicated for the management of moderately severe to severe essential hypertension and uncomplicated malignant hypertension. This policy supports prior authorization decisions for use in those clinical contexts and is not a substitute for clinical judgment; providers retain responsibility for individual treatment decisions.

Definitions and Role of Policy

Vecamyl (mecamylamine) — product attributes

Generic nameMecamylamine (Vecamyl)

FormulationOral tablet; tablet strength listed in brief: 2.5 mg

FDA‑approved indicationManagement of moderately severe to severe essential hypertension and uncomplicated malignant hypertension

Typical initial dosing (brief)2.5 mg PO BID

Role of clinical policy

Policy roleThis clinical policy does not constitute medical advice and is not intended to dictate how providers should practice medicine; providers retain independent professional judgment and responsibility for treatment decisions.

Policy Summary

Payermhn

PolicyMecamylamine (Vecamyl) for hypertension

Policy CodePolicy CP.PMN.136

Change TypeStep therapy bypass added (IL)Commercial approval durations revised

Effective DateJun 1, 2017

Next Review Date

Key ActionSubmit prior authorization with documentation showing diagnosis, age ≥18, and failure of three formulary antihypertensive classes (unless IL HIM bypass applies).

SourceLink

On This Page

Medication history demonstrating trials and outcomes of prior antihypertensive agents.

Clinical rationale and records if denying/refusing step therapy due to adverse effects or contraindications.

For off‑label indications, provide evidence per applicable off‑label policies: CP.CPA.09 (Commercial), HIM.PA.154 (HIM), CP.PMN.53 (Medicaid).

Step Therapy

Step Therapy Requirement — fail ≥3 antihypertensive classes

Step therapy requires failure of a combination of three formulary antihypertensive agents from different classes at maximally indicated doses, unless clinically significant adverse effects are experienced or all are contraindicated.

Member must have tried and failed ≥3 antihypertensive classes (combination therapy) at adequate doses.
See Appendix D for rationale and Appendix B for dosing guidance.
Approval duration for initial therapy: 6 months (Commercial update noted in references).

Step Therapy

Illinois Step Therapy Bypass (IL HB 5395)

Per Illinois HB 5395, the step therapy requirement does not apply to Illinois HIM requests as of 01/01/2026. When applicable, the statutory bypass supersedes the normal step-therapy requirement.

IL HIM step therapy bypass effective 01/01/2026 (IL HB 5395).
Providers in Illinois HIM should indicate applicability during PA submission to avoid unnecessary denials or delays.

Note

Off‑Label Request Routing

Off‑label or non‑FDA indications may be denied if sufficient off‑label efficacy/safety documentation is not provided. Follow the plan-specific off‑label policies when submitting requests for non‑FDA uses.

Commercial: CP.CPA.09; HIM: HIM.PA.154; Medicaid: CP.PMN.53.
Include literature, clinical rationale, and prior treatment history to support off‑label use.

Note

Authorization Duration & Prior Review Notes

Authorization durations and prior-review notes: initial approval is 6 months and continued approval is 12 months per the Commercial line update; template and reference changes have been applied periodically and may affect authorization workflows.

2Q2024 update: Commercial approval durations set to 6 months (initial) and 12 months (continued).
Template changes applied 10/03/22 may affect continued therapy criteria and forms.
2Q2025: step therapy bypass for IL HIM added; providers should account for this in submissions.

Denial Risk

Contractual Binding and Implications

Providers and members are contractually bound to the terms of this policy. Failure to provide required documentation or follow PA processes may result in denial and limits appeal rights.

Submitting services or claims constitutes agreement to policy terms when no separate contract exists.
Incomplete documentation or failure to follow PA/step therapy may lead to claim denial and affect appeal outcomes.

Provider responsibility

Providers are expected to exercise professional medical judgment in providing the most appropriate care and are solely responsible for medical advice and treatment of members.

Member guidanceMembers should consult with their treating physician for diagnosis and treatment decisions.

Medicaid precedence

Medicaid precedenceWhen state Medicaid coverage provisions conflict with this clinical policy, state Medicaid coverage provisions take precedence.

Action for providersRefer to the applicable state Medicaid manual for coverage provisions pertaining to this clinical policy.

ScopeApplies specifically to Medicaid members covered under state programs where conflicts arise.